ServiceNow heads into its July 22 earnings print with the stock down sharply from last week's highs — reversing much of the rally that prompted the previous note — and with short sellers moving in the opposite direction to what the price action implies.
The week's most striking development is the price reversal. NOW fell 5.3% over the past five days to close at $104.85, unwinding a significant portion of the 11.5% surge documented in the July 8 note. The pullback is broad rather than stock-specific: CRM slid 1.2% on the week, WDAY dropped 2.7%, and ADBE fell 0.3%, while GWRE, HUBS, and all managed modest gains. was the session's biggest loser among peers, falling 7.4% on Tuesday alone. The pattern suggests NOW's weakness is partly sector-driven but steeper than the peer average, with the stock now sitting roughly 35% below the consensus analyst target of $141.
Short positioning tells a less aggressive story than the price slide might suggest. Short interest has actually fallen, not risen, declining about 4.6% over the past week to roughly 28.8% of the free float — the lowest level in six weeks. That follows a steady bleed from the early-June peak near 32% of the float. The borrow market remains completely unthreatening: cost to borrow is running near 0.37%, down 13% on the week, and availability is exceptionally loose at roughly 20x the shares already borrowed. There is no sign of squeeze pressure, and no sign of fresh short conviction either. Options traders are similarly relaxed: the put/call ratio dipped to 0.73 on Tuesday, modestly below its 20-day average of 0.75, suggesting no unusual demand for downside protection heading into results.
The Street remains broadly constructive but with growing valuation discipline. Two analyst moves landed on Tuesday. Oppenheimer raised its target to $140 from $130, keeping an Outperform rating, while Citigroup trimmed marginally to $156 from $158, also retaining Buy. Both upgrades sit well above current levels, but Goldman Sachs cut its target to $145 from $163 last week, a more pointed signal that even the bulls are recalibrating after the CRPO miss documented in the previous note. UBS kept its Neutral rating and raised its target to $115 — a sidelined signal given the stock trades near $105. The analyst recommendation divergence factor ranks in the 94th percentile, meaning analyst opinion is more spread than almost any other name in the universe, which itself reflects how contested the earnings narrative has become. The bull case centres on FY25 NNACV of $2.3 billion and a credible path to 17%+ organic subscription revenue growth. The bear case centres on the record CRPO miss and the 72% year-on-year collapse in Federal Government obligations.
Earnings history adds useful context. The two most recent prints delivered sharp negative reactions: a 12.5% one-day drop and a 15.3% one-day drop respectively on the April prints. The May release was far calmer, with a 1.1% decline on day one followed by a 5.3% five-day recovery. The range of outcomes in recent quarters has been unusually wide, and the stock enters this week's print from a lower base than it occupied ahead of any of those events.
With July 22 now one week out, the key tension is whether the CRPO deterioration reflected a one-quarter anomaly or a more durable shift in Federal spending — and whether the AI platform narrative can carry enough weight to offset that uncertainty.
See the live data behind this article on ORTEX.
Open NOW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
